Sienna Cancer Diagnostics Ltd, (ASX:SDX), a medical technology company developing and commercialising innovative cancer-related tests, is pleased to notify shareholders of a FNN interview with Sienna’s CEO, which provides an update on its business progress, upcoming milestones and the product expansion strategy.
For more information, download the attached PDF.
Download this document
